Companies / Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc.
BLPHCIK 1600132
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 19, 2015 | Holt Matthew S. Director | Buy Open-market buy | Common Stock | $12.84M | +1.1M +28.24% | 4,859,885 | high |
| Feb 19, 2015 | Weinstein Adam Director | Buy Open-market buy | Common Stock | $12.84M | +1.1M +28.24% | 4,859,885 | high |
| Feb 19, 2015 | New Mountain Investments II, LLC 10% owner | Buy Open-market buy | Common Stock | $12.84M | +1.1M +28.24% | 4,859,885 | high |
| May 18, 2023 | Puissance Life Science Opportunities Fund VI 10% owner | Sell Open-market sale | Common Stock | $5.30M | -560K -31.62% | 1,211,262 | medium |
| Feb 19, 2015 | Luehring Jens Director | Buy Open-market buy | Common Stock | $4.31M | +359K +28.24% | 1,629,804 | high |
| Feb 19, 2015 | Linde North America, Inc. 10% owner | Buy Open-market buy | Common Stock | $4.31M | +359K +28.24% | 1,629,804 | high |
| Feb 19, 2015 | Arch Venture Fund VI LP 10% owner | Buy Open-market buy | Common Stock | $2.55M | +213K +28.24% | 965,660 | high |
| Feb 19, 2015 | Nelsen Robert Director | Buy Open-market buy | Common Stock | $2.55M | +213K +28.24% | 965,660 | high |